209 studies found for:    S1105
Show Display Options
Rank Status Study
1 Active, not recruiting S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
Condition: Breast Cancer
Intervention: Behavioral: Text message reminder
2 Recruiting S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma
Condition: Stomach Neoplasms
Intervention: Drug: S-1; Oxaliplatin; 5-Fu; Leucovorin Calcium
3 Recruiting Boston Scientific Post Market S-ICD Registry
Condition: Tachycardia, Ventricular
Intervention: Device: S-ICD System
4 Active, not recruiting A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma, B-Cell, Lymphoma, Follicular
Interventions: Drug: DCDS4501A;   Drug: DCDT2980S;   Drug: rituximab [MabThera/Rituxan]
5 Terminated A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.
Condition: Diabetic Neuropathies
Interventions: Drug: Placebo;   Drug: [S,S]-Reboxetine
6 Active, not recruiting Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis
Condition: Moderate to Severe Palmoplantar Psoriasis
Interventions: Biological: secukinumab 150 mg;   Biological: secukinumab 300 mg;   Biological: Placebo
7 Active, not recruiting 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Interventions: Drug: Secukinumab (75 mg);   Drug: Secukinumab (150 mg);   Drug: Placebo
8 Completed
Has Results
Study of Adalimumab in Patients With Axial Spondyloarthritis
Condition: Axial Spondyloarthritis
Interventions: Biological: Adalimumab;   Biological: Placebo;   Biological: Open-label Adalimumab
9 Completed Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Conditions: Acquired Bleeding Disorder;   Intracerebral Haemorrhage
Intervention: Drug: activated recombinant human factor VII
10 Active, not recruiting The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
Conditions: Diabetes;   Diabetes Mellitus, Type 1
Interventions: Drug: liraglutide;   Drug: placebo
11 Completed GS-7977 and Ribavirin in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Condition: Hepatitis C
Interventions: Drug: GS-7977;   Drug: RBV;   Drug: Placebo to match GS-7977;   Drug: Placebo to match RBV
12 Completed A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
Conditions: Stomach Neoplasms;   Esophageal Neoplasms
Interventions: Drug: BMS-833923;   Drug: Cisplatin;   Drug: Capecitabine
13 Recruiting Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Condition: Atherosclerosis
Interventions: Drug: Canakinumab;   Drug: Placebo
14 Not yet recruiting A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF Inhibitors
Condition: Ulcerative Colitis
Interventions: Drug: etrolizumab;   Drug: infliximab;   Other: placebo (IV);   Other: placebo (injection)
15 Completed Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Conditions: Acquired Bleeding Disorder;   Intracerebral Haemorrhage
Intervention: Drug: activated recombinant human factor VII
16 Unknown  Serial Echocardiography After Subarachnoid Hemorrhage
Conditions: Subarachnoid Hemorrhage;   Myocardial Stunning;   Takotsubo Cardiomyopathy
Intervention:
17 Recruiting 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Biological: Secukinumab;   Biological: Placebo
18 Completed A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
Condition: Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Interventions: Other: Background care;   Drug: Placebo;   Drug: dalcetrapib
19 Recruiting 16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
Condition: Anklyosing Spondylitis
Interventions: Drug: Secukinumab (75 mg);   Drug: Placebo;   Drug: Secukinumab (150 mg)
20 Not yet recruiting The Pain Suppressive Effect of Alternative Spinal Cord Stimulation Frequencies
Conditions: Failed Back Surgery Syndrome;   Neuropathic Pain
Interventions: Device: Spinal Cord Stimulation;   Device: Group 1;   Device: Group 2

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years